This fund holds major U.S. health-care companies and mega-cap foreign firms such as Novartis NVS, Roche, and Sanofi SNY , with foreign firms making up about 37% of the fund's assets. We would caution investors, however, that the dynamics
Analyst : More Details about the Sanofi /MannKind Deal Emerge from the Morgan ..... 65/35 profit sharing deal with Sanofi will yield them the equivalent of ..... terms of the agreement mean that Sanofi (NYSE: SNY ) will be fronting MNKD's development
Sept 10 (Reuters) - Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA 's blockbuster insulin, Lantus.
By Balanced Investing : Sanofi (NYSE: SNY ) is a healthcare company engaged ..... In my article, I will analyze Sanofi 's pipeline and its valuation. Positive Data from Sanofi and Regeneron Pharmaceutical's
announced positive results from four Phase III trials for its potential blockbuster drug, alirocumab. Regeneron and Sanofi (NYSE: SNY ) have also purchased a priority review voucher for alirocumab U.S. FDA submission, which has given them a chance
include AMGN and REGN, REGN's joint venture partner Sanofi (NYSE: SNY ), Pfizer (NYSE: PFE ) and Eli Lilly (NYSE: LLY ..... and European marketing approval late last month; REGN/ SNY intend to file by year-end. Pfizer and Lilly lag
basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared to Sanofi 's (NYSE: SNY ) Lantus ( insulin glargine ) at 26 and 52 weeks in patients with Type 1 diabetes. Both trials showed the rate
Sanofi 's strong ..... should mean Sanofi will have ..... insulin market, Sanofi 's Lantus ..... lifestyles. Sanofi 's increasingly ..... exemplary. Since Chris Viehbacher took over ..... understanding of Sanofi 's home country ..... May 2010, Serge Weinberg took over
vaccine in the world, Prevnar 13, the company's vaccine division has been trailing those of Merck (NYSE: MRK ), Sanofi (NYSE: SNY ) and GlaxoSmithKline (NYSE: GSK ). Some recent developments though have allowed Pfizer to close the gap. Last
Sept 4 (Reuters) - Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA 's approved drug, Lantus, in reducing blood sugar levels in late-stage trials.